No Data
Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55
Mind Medicine Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.
Mind Medicine's Strategic Advancements and Clinical Progress Drive Buy Rating
CCORF Maintains Mind Medicine(MNMD.US) With Buy Rating, Raises Target Price to $16
No Data
No Data
